AstraZeneca COVID-19 vaccine

GPTKB entity

Predicate	Object
gptkbp:instanceOf	vaccine
gptkbp:alsoKnownAs	gptkb:Vaxzevria gptkb:AZD1222 gptkb:Covishield
gptkbp:approvedBy	gptkb:European_Union gptkb:India gptkb:United_Kingdom gptkb:World_Health_Organization December 2020
gptkbp:category	gptkb:COVID-19_pandemic 2020 introductions AstraZeneca products Vaccines based on viral vectors
gptkbp:contains	genetic material encoding SARS-CoV-2 spike protein
gptkbp:developedBy	gptkb:University_of_Oxford gptkb:AstraZeneca
gptkbp:dosesRequired	2
gptkbp:efficacyAgainstSymptomaticCOVID19	~70%
gptkbp:emergencyServices	gptkb:World_Health_Organization
https://www.w3.org/2000/01/rdf-schema#label	AstraZeneca COVID-19 vaccine
gptkbp:intervalBetweenDoses	4–12 weeks
gptkbp:manufacturer	gptkb:SK_Bioscience gptkb:Serum_Institute_of_India gptkb:Catalent gptkb:Fiocruz gptkb:IDT_Biologika
gptkbp:notRecommendedFor	children under 18 (in some countries)
gptkbp:routeOfAdministration	intramuscular injection
gptkbp:shelfLife	6 months at 2–8°C
gptkbp:sideEffect	fever fatigue headache muscle pain rare blood clotting events
gptkbp:storage	2–8°C
gptkbp:target	gptkb:COVID-19
gptkbp:technology	chimpanzee adenovirus vector
gptkbp:type	viral vector vaccine
gptkbp:usedInCOVAX	yes
gptkbp:WHOEmergencyUseListing	February 2021
gptkbp:bfsParent	gptkb:COVID-19 gptkb:COVID-19_pandemic
gptkbp:bfsLayer	4